No Data
CSPC Innovation Pharmaceutical's Unit Gets NMPA's Nod for Asthma Drug
CSPC Innovation Pharmaceutical (300765.SZ) has received a cumulative Shareholding of 1.7152 million shares from its controlling Shareholder, Enbipu Pharmaceuticals.
CSPC Innovation Pharmaceutical (300765.SZ) announced that the implementation period of the shareholding plan by its controlling shareholder Enbiopu Pharmaceutical has exceeded half the time, and...
CSPC Innovation Pharmaceutical (300765.SZ): The holding subsidiary has obtained the pharmaceutical registration certificate for a new indication of injectable omalizumab.
On February 10, Gelonghui reported that CSPC Innovation Pharmaceutical (300765.SZ) announced that its subsidiary CSPC PHARMA JuShi Biotechnology Co., Ltd. (referred to as "JuShi Biotechnology") recently received notification from the National Medical Products Administration, approving the use of Omilizumab injection (commodity name: Enyitan) for the treatment of moderate to severe persistent allergic asthma. This marks the second indication approved for Enyitan in China. Enyitan is a humanized monoclonal antibody targeting immunoglobulin E (IgE) developed by the group, and is a biosimilar to Zebulon. The newly approved indication is for moderate to severe persistent allergic asthma.
CSPC Innovation Pharmaceutical (300765.SZ): The holding subsidiary SYS6017 has received the notification of approval for a clinical trial of its shingles mRNA vaccine.
On February 7, Gelonghui reported that CSPC Innovation Pharmaceutical (300765.SZ) announced that its holding subsidiary CSPC PHARMA Jushi Biopharmaceutical Co., Ltd. (referred to as "Jushi Biopharma") recently received the approval from the National Medical Products Administration for the clinical trial approval notice for SYS6017, which will soon commence clinical trials. SYS6017 consists of mRNA molecules encoding the varicella-zoster virus (VZV) glycoprotein E (gE protein) wrapped in lipid nanoparticles and is intended for the prevention of herpes zoster infection.
CSPC Innovation Pharmaceutical Co., Ltd.'s (SZSE:300765) Popularity With Investors Is Clear
Express News | CSPC Innovation Says to Buy Stake in Biopharmaceutical Firm in a Deal to Be Settled by New Shares Issue, Cash